Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2023 07:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
January 11, 2023 08:45 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...
December 13, 2022 16:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators

Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI...
November 03, 2022 16:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
July 28, 2022 08:00 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
May 13, 2022 08:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
May 12, 2022 08:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
May 11, 2022 08:35 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR

PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
May 09, 2022 16:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
April 22, 2022 08:00 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...